

Abstract of the Disclosure

The present invention relates to the use of creatine compounds including creatine, creatine phosphate or analogs of creatine, such as creatine-pyruvate, creatine ascorbate, cyclocreatine, 3 guanidinopropionic acid, guanidinoacetate, homocyclocreatine for preventing or treating TSE diseases of the nervous system. The Creatine compounds which can be used in the present method include (1) creatine, creatine phosphate and analogs of these compounds which can act as substrates or substrate analogs for creatine kinase; (2) molecules that mimic the biological activity of creatine (3) molecules that modulate the creatine kinase system.